Formulation Development of Albendazole-Loaded Self-Microemulsifying Chewable Tablets to Enhance Dissolution and Bioavailability.

Somchai Sawatdee, Apichart Atipairin, Attawadee Sae Yoon, Teerapol Srichana, Narumon Changsan, Tan Suwandecha
Author Information
  1. Somchai Sawatdee: Drug and Cosmetics Excellence Center, Walailak University, Thasala, Nakhon Si Thammarat 80161, Thailand. somchai086@hotmail.com.
  2. Apichart Atipairin: Drug and Cosmetics Excellence Center, Walailak University, Thasala, Nakhon Si Thammarat 80161, Thailand. apichart.at@wu.ac.th.
  3. Attawadee Sae Yoon: Drug and Cosmetics Excellence Center, Walailak University, Thasala, Nakhon Si Thammarat 80161, Thailand. attawadee.sa@wu.ac.th.
  4. Teerapol Srichana: Drug Delivery System Excellence Center and Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand. teerapol.s@psu.ac.th.
  5. Narumon Changsan: Faculty of Pharmacy, Rangsit University, Pathumtani 12000, Thailand. narumon.c@rsu.ac.th.
  6. Tan Suwandecha: Department of Pharmacology, Faculty of Sciences, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand. tan.s@psu.ac.th.

Abstract

Albendazole is an anthelmintic agent with poor solubility and absorption. We developed a chewable tablet (200 mg drug equivalent), containing a self-microemulsifying drug delivery system (SMEDDS), with oral disintegrating properties. The emulsion was developed using sesame and soybean oils along with surfactant/co-surfactants, and the tablets were prepared by wet granulation using superdisintegrants and adsorbents. Infra-red (IR) spectral studies revealed no interaction between the drug and excipients, and all physical and chemical parameters were within acceptable limits. Stability studies for the formulation indicated no significant change over time. An in vitro release study indicated 100% drug release within 30 min, and in vivo plasma concentrations indicated that the area under the curve (AUC) of albendazole in rats administered SMEDDS chewable tablets was significantly higher than in those administered commercial tablets or powder (-value < 0.05). The systemic bioavailability of albendazole achieved through the SMEDDS tablets was 1.3 times higher than that achieved by the administration of comparable quantities of albendazole commercial tablets. This was due to the higher dissolution of albendazole SMEDDS in the chewable tablets. We conclude that the SMEDDS chewable formulation can be used to improve the dissolution and systemic availability of poorly water-soluble drugs.

Keywords

References

  1. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):225-32 [PMID: 15878252]
  2. Biomed Pharmacother. 2004 Apr;58(3):173-82 [PMID: 15082340]
  3. Eur J Pharm Biopharm. 2002 Mar;53(2):147-53 [PMID: 11879996]
  4. Carbohydr Polym. 2014 Dec 19;114:365-374 [PMID: 25263903]
  5. Int J Pharm. 2011 Nov 25;420(1):1-10 [PMID: 21884771]
  6. Arch Pharm Res. 2013 Aug;36(8):993-1003 [PMID: 23595551]
  7. Eur J Pharm Biopharm. 2009 Aug;72(3):539-45 [PMID: 19298857]
  8. Pharmaceutics. 2018 Jun 29;10(3): [PMID: 29966249]
  9. Pharmaceutics. 2018 Sep 05;10(3): [PMID: 30189624]
  10. Antimicrob Agents Chemother. 2004 Mar;48(3):1051-4 [PMID: 14982808]
  11. Asian J Pharm Sci. 2018 Nov;13(6):536-545 [PMID: 32104428]
  12. Pharm Dev Technol. 2019 Jan;24(1):1-11 [PMID: 28135896]
  13. Int J Pharm. 2002 Mar 20;235(1-2):247-65 [PMID: 11879759]
  14. Acta Pharm. 2012 Dec;62(4):563-80 [PMID: 24000442]
  15. Acta Trop. 2003 May;86(2-3):141-59 [PMID: 12745134]
  16. Eur J Pharm Biopharm. 2017 Jun;115:268-275 [PMID: 28323109]
  17. Adv Drug Deliv Rev. 2008 Mar 17;60(6):625-37 [PMID: 18068260]
  18. J Pharm Anal. 2016 Aug;6(4):226-234 [PMID: 29403987]
  19. J Colloid Interface Sci. 2012 Jun 15;376(1):133-9 [PMID: 22480397]
  20. J Pharm Pharmacol. 2010 Sep;62(9):1112-20 [PMID: 20796189]
  21. Mol Pharm. 2012 Sep 4;9(9):2750-60 [PMID: 22870936]
  22. Parasitology. 2000;121 Suppl:S113-32 [PMID: 11386684]
  23. Int J Pharm. 2011 Nov 28;420(2):412-8 [PMID: 21944892]
  24. J Young Pharm. 2011 Jan;3(1):4-8 [PMID: 21607048]
  25. Int J Pharm. 2018 Sep 5;548(1):263-275 [PMID: 29969713]
  26. J Anal Toxicol. 1994 Mar-Apr;18(2):86-90 [PMID: 8207939]
  27. Eur J Pharm Biopharm. 2012 Feb;80(2):289-97 [PMID: 22119666]
  28. Curr Drug Deliv. 2017;14(8):1078-1096 [PMID: 27557673]
  29. Int J Pharm. 2016 Jun 15;506(1-2):302-11 [PMID: 27125455]
  30. Int J Pharm. 2014 Sep 10;472(1-2):40-7 [PMID: 24929011]
  31. Infect Chemother. 2018 Mar;50(1):1-10 [PMID: 29637747]

Grants

  1. WU60117, WU60117-2/Walailak University

Word Cloud

Created with Highcharts 10.0.0tabletschewableSMEDDSalbendazoledrugindicatedhigherdissolutiondevelopedtabletusingstudieswithinformulationreleaseadministeredcommercialsystemicbioavailabilityachievedAlbendazoleanthelminticagentpoorsolubilityabsorption200mgequivalentcontainingself-microemulsifyingdeliverysystemoraldisintegratingpropertiesemulsionsesamesoybeanoilsalongsurfactant/co-surfactantspreparedwetgranulationsuperdisintegrantsadsorbentsInfra-redIRspectralrevealedinteractionexcipientsphysicalchemicalparametersacceptablelimitsStabilitysignificantchangetimevitrostudy100%30minvivoplasmaconcentrationsareacurveAUCratssignificantlypowder-value<00513timesadministrationcomparablequantitiesdueconcludecanusedimproveavailabilitypoorlywater-solubledrugsFormulationDevelopmentAlbendazole-LoadedSelf-MicroemulsifyingChewableTabletsEnhanceDissolutionBioavailabilitypharmacokineticsself-microemulsion

Similar Articles

Cited By